[go: up one dir, main page]

FR2868422B1 - Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases - Google Patents

Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Info

Publication number
FR2868422B1
FR2868422B1 FR0403354A FR0403354A FR2868422B1 FR 2868422 B1 FR2868422 B1 FR 2868422B1 FR 0403354 A FR0403354 A FR 0403354A FR 0403354 A FR0403354 A FR 0403354A FR 2868422 B1 FR2868422 B1 FR 2868422B1
Authority
FR
France
Prior art keywords
kinases
inhibitors
preparation
pharmaceutical use
pyridine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0403354A
Other languages
English (en)
Other versions
FR2868422A1 (fr
Inventor
Sylvie Wentzler
Ahmad Youssef El
Romme Bruno Filoche
Conception Nemecek
Corinne Venot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0403354A priority Critical patent/FR2868422B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to PCT/FR2005/000773 priority patent/WO2005095399A2/fr
Priority to CA002558923A priority patent/CA2558923A1/fr
Priority to TW094109913A priority patent/TW200602344A/zh
Priority to CNA2005800137910A priority patent/CN1950083A/zh
Priority to MXPA06011161A priority patent/MXPA06011161A/es
Priority to ARP050101222A priority patent/AR048344A1/es
Priority to EP05746934A priority patent/EP1732546A2/fr
Priority to KR1020067021575A priority patent/KR20070014151A/ko
Priority to AU2005229452A priority patent/AU2005229452A1/en
Priority to JP2007505596A priority patent/JP4841543B2/ja
Priority to BRPI0509564-6A priority patent/BRPI0509564A/pt
Priority to UY28835A priority patent/UY28835A1/es
Publication of FR2868422A1 publication Critical patent/FR2868422A1/fr
Application granted granted Critical
Publication of FR2868422B1 publication Critical patent/FR2868422B1/fr
Priority to IL178310A priority patent/IL178310A0/en
Priority to US11/541,051 priority patent/US7528147B2/en
Priority to US12/410,135 priority patent/US7968566B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR0403354A 2004-03-31 2004-03-31 Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases Expired - Fee Related FR2868422B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR0403354A FR2868422B1 (fr) 2004-03-31 2004-03-31 Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2007505596A JP4841543B2 (ja) 2004-03-31 2005-03-30 新規なピロロ（２，３−ｂ）ピリジン誘導体、製造およびキナーゼ阻害薬の形態でのそれの医薬的使用
TW094109913A TW200602344A (en) 2004-03-31 2005-03-30 Novel pyrrolo(2, 3-b)pyridine derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CNA2005800137910A CN1950083A (zh) 2004-03-31 2005-03-30 新吡咯并(2,3－b)吡啶衍生物，它们的制备与它们作为激酶抑制剂的药物用途
MXPA06011161A MXPA06011161A (es) 2004-03-31 2005-03-30 Nuevos derivados de la pirrolo(2,3-b)piridina, su preparacion y su utilizacion farmaceutica como inhibidores de cinasas.
ARP050101222A AR048344A1 (es) 2004-03-31 2005-03-30 Derivados de la pirrolo(2,3-b)piridina, su preparacion y su utilizacion farmaceutica como inhibidores de kinasas
EP05746934A EP1732546A2 (fr) 2004-03-31 2005-03-30 Nouveaux derives pyrrolo(2,3-b)pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR1020067021575A KR20070014151A (ko) 2004-03-31 2005-03-30 신규 피롤로(2,3-ｂ)피리딘 유도체, 이의 제법 및 키나제억제제 형태로서의 이의 제약 용도
PCT/FR2005/000773 WO2005095399A2 (fr) 2004-03-31 2005-03-30 Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA002558923A CA2558923A1 (fr) 2004-03-31 2005-03-30 Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
BRPI0509564-6A BRPI0509564A (pt) 2004-03-31 2005-03-30 derivados pirrolo(2,3-b)piridina, respectivo preparo e respectiva utilização farmacêutica como inibidores de quinases
AU2005229452A AU2005229452A1 (en) 2004-03-31 2005-03-30 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
UY28835A UY28835A1 (es) 2004-03-31 2005-03-31 Nuevos derivados de la pirrolo (2, 3-b) piridina, su preparación y su utilización farmcéutica como inhibidores de cinasas.
IL178310A IL178310A0 (en) 2004-03-31 2006-09-26 Novel pyrrolo (2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
US11/541,051 US7528147B2 (en) 2004-03-31 2006-09-29 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
US12/410,135 US7968566B2 (en) 2004-03-31 2009-03-24 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0403354A FR2868422B1 (fr) 2004-03-31 2004-03-31 Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (2)

Publication Number Publication Date
FR2868422A1 FR2868422A1 (fr) 2005-10-07
FR2868422B1 true FR2868422B1 (fr) 2006-07-14

Family

ID=34946084

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0403354A Expired - Fee Related FR2868422B1 (fr) 2004-03-31 2004-03-31 Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Country Status (15)

Country Link
US (2) US7528147B2 (fr)
EP (1) EP1732546A2 (fr)
JP (1) JP4841543B2 (fr)
KR (1) KR20070014151A (fr)
CN (1) CN1950083A (fr)
AR (1) AR048344A1 (fr)
AU (1) AU2005229452A1 (fr)
BR (1) BRPI0509564A (fr)
CA (1) CA2558923A1 (fr)
FR (1) FR2868422B1 (fr)
IL (1) IL178310A0 (fr)
MX (1) MXPA06011161A (fr)
TW (1) TW200602344A (fr)
UY (1) UY28835A1 (fr)
WO (1) WO2005095399A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
RU2012117230A (ru) 2009-09-30 2013-11-10 Президент Энд Феллоуз Оф Гарвард Колледж Способы модулирования аутофагии путем модулирования продуктов, усиливающих аутофагию генов
CN102070638A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种六氢-吡咯[3,4-c]吡咯-1-酮衍生物的制备方法
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
CA2930297C (fr) 2013-11-13 2022-04-05 Vertex Pharmaceuticals Incorporated Procedes de preparation d'inhibiteurs de la replication des virus de la grippe
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN112961159B (zh) * 2020-03-05 2022-07-01 四川大学华西医院 氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12514A (en) * 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
SE0102204D0 (sv) * 2001-06-21 2001-06-21 Leif Isaksson New method
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (fr) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Also Published As

Publication number Publication date
EP1732546A2 (fr) 2006-12-20
IL178310A0 (en) 2007-02-11
MXPA06011161A (es) 2007-12-10
AU2005229452A1 (en) 2005-10-13
US7968566B2 (en) 2011-06-28
WO2005095399A2 (fr) 2005-10-13
US20090233956A1 (en) 2009-09-17
TW200602344A (en) 2006-01-16
CA2558923A1 (fr) 2005-10-13
US20070093480A1 (en) 2007-04-26
BRPI0509564A (pt) 2007-09-25
JP4841543B2 (ja) 2011-12-21
FR2868422A1 (fr) 2005-10-07
JP2007530645A (ja) 2007-11-01
AR048344A1 (es) 2006-04-19
US7528147B2 (en) 2009-05-05
UY28835A1 (es) 2005-10-31
WO2005095399A3 (fr) 2006-06-01
KR20070014151A (ko) 2007-01-31
CN1950083A (zh) 2007-04-18

Similar Documents

Publication Publication Date Title
MA28941B1 (fr) Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MA28732B1 (fr) Nouveaux derives d'uree cyclique, leur preparation, et leur uttilisation pharmaceutique comme inhibiteurs de la kinase
FR2850652B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2864084B1 (fr) Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
FR2896503B1 (fr) Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MA28366A1 (fr) Derives de piperidinylalkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
MA28756B1 (fr) Derives substitues d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de la kinase
MA28365A1 (fr) Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
WO2007013896A3 (fr) Composes modulant l'activite de c-kit et c-fms et utilisations
MA28370A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine-carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
FR2906250B1 (fr) Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
EP2395004A3 (fr) Dérivés de pyrrolo [2,3-b]pyridine en tant qu'inhibiteurs de la protéine kinase
FR2918986B1 (fr) Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
MA28882B1 (fr) Nouveaux derives de pyrimidine et leur utilisation comme modulateurs de ppar-alpha
WO2005094531A3 (fr) Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
NO20013335L (no) Anvendelse av 4-H-1-benzopyran-4-on-derivater som inhibitorer av glatt muskelcelle proliferering
MA28753B1 (fr) Derives cycliques d'uree substitues par un heterocycle, leur preparation et leur utilisation pharmaceutique en tant qu'inhibiteurs de kinases
MA26976A1 (fr) Derives du tetrahydropyridine, leur preparation et leur utilisation comme inhibiteur de proliferation de cellules
FR2868780B1 (fr) Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
IL178310A0 (en) Novel pyrrolo (2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
MA28367A1 (fr) Derives d'heteroaryl-alkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
EP1756036A4 (fr) Derives indenes et leur procede d'elaboration
FR2947550B1 (fr) Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20121130